 |
|
Prolonged Serum Levodopa Levels With Controlled-Release Carbidopa-Levodopa in the Treatment of Parkinson's Disease
J. Thomas Hutton, MD, PhD;
J. William Albrecht, PhD;
Gustavo C. Román, MD;
Michael T. Kopetzky, MD
Arch Neurol. 1988;45(1):55-57.
Abstract
• Twenty parkinsonian patients (Hoehn and Yahr scale, I through III) were treated with controlled-release carbidopa-levodopa (CR-2 or CR-3) and standard carbidopa-levodopa (Sinemet, 25 mg/100 mg) in a double-blind, crossover pharmacokinetic and clinical efficacy study. The controlled-release agents had a slower rise to peak plasma values and flatter pharmacokinetic curves than did the standard. The area under the curve for CR-3 was significantly increased by 55.5% as compared with standard agent and by 84.2% as compared with CR-2. No differences in clinical efficacy were found between controlled-release agents and the standard agent for this group of parkinsonian patients with mild to moderate severity. The dissociation between the prolonged serum levodopa levels and unimproved clinical efficacy may have resulted from the absence of patients with prominent motor fluctuations and/or substantial serum levodopa variability that was especially prominent with CR-3.
Author Affiliations
From the Departments of Medical and Surgical Neurology (Drs Hutton and Román) and Physiology (Dr Kopetzky), Texas Tech University Health Sciences Center, Lubbock; and Medical Research Services, Veterans Administration Medical Center, Augusta, Ga (Dr Albrecht).
Footnotes
Accepted for publication Aug 6, 1987.
Reprint requests to Department of Medical and Surgical Neurology, Texas Tech University Health Sciences Center, Lubbock, TX 79430 (Dr Hutton).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Treatment of Chronic Parkinson's Disease With Controlled-Release Carbidopa/Levodopa
Hutton et al.
Arch Neurol 1988;45:861-864.
ABSTRACT
|
